Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | FNTA | P49354 | 1/20 | 0.36 |
| ▸ | FNTB | P49356 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 1,6-Hexanediol SCHEMBL1982872 | 1.00 | GPR84 (0.41) | GPR84FFAR1FFAR4ALDH1A1TSHR | |
| SCHEMBL1982601 | 1.00 | GPR84 (0.41) | GPR84FFAR1FFAR4ALDH1A1TSHR | |
| SCHEMBL4581426 | 1.00 | GPR84 (0.41) | GPR84FFAR1FFAR4ALDH1A1TSHR | |
| 1,5-Pentanediol SCHEMBL25273701 | 1.00 | GPR84 (0.41) | GPR84FFAR1FFAR4ALDH1A1TSHR | |
| SCHEMBL4581829 | 1.00 | GPR84 (0.41) | GPR84FFAR1FFAR4ALDH1A1TSHR | |
| SCHEMBL25260910 | 1.00 | GPR84 (0.41) | GPR84FFAR1FFAR4ALDH1A1TSHR | |
| 1,4-Butanediol SCHEMBL4580412 | 0.98 | ALDH1A1 (0.39) | GPR84FFAR1FFAR4ALDH1A1TSHR | |
| 1,3-Propanediol SCHEMBL4578759 | 0.93 | ALDH1A1 (0.39) | GPR84FFAR1FFAR4ALDH1A1TSHR | |
| Octanol SCHEMBL28864643 | 0.90 | TSHR (0.48) | GPR84FFAR1FFAR4ALDH1A1TSHR | |
| Ethylene Glycol SCHEMBL8420929 | 0.88 | ALDH1A1 (0.41) | ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4194523-A1 | CYANOACRYLATE ADHESIVE COMPOSITION | Cuantum Medical Cosmetics, S.L. (ES) | 2023-06-14 | — | — | EP | claimed |
| EP-4194523-A1 | CYANOACRYLATE ADHESIVE COMPOSITION | Cuantum Medical Cosmetics, S.L. (ES) | 2023-06-14 | — | — | EP | disclosed |
| CN-110283538-A | A kind of identifiable instant drying adhesive and preparation method thereof | 上海康达化工新材料股份有限公司 | 2019-09-27 | — | — | CN | disclosed |
| US-9096778-B2 | Cyanoacrylate adhesive with improved water resistance | Henkel IP & Holding GmbH (DE) | 2015-08-04 | — | — | US | disclosed |
| CN-103476885-B | Cyanoacrylate adhesive with improved water resistance | HENKEL IP HOLDING LTD | 2015-06-10 | — | — | CN | disclosed |
| CN-103476885-A | Cyanoacrylate adhesive with improved water resistance | HENKEL IRELAND LTD | 2013-12-25 | — | — | CN | disclosed |
| EP-2511355-B1 | Cyanoacrylate adhesive with improved water resistance | HENKEL IRELAND LTD (DE) | 2013-10-23 | — | — | EP | disclosed |
| US-20130174981-A1 | CYANOACRYLATE ADHESIVE WITH IMPROVED WATER RESISTANCE | HENKEL IRELAND LIMITED (DE) | 2013-07-11 | — | — | US | disclosed |
| EP-2511355-A1 | Cyanoacrylate adhesive with improved water resistance | Henkel Ireland Ltd. (IE) | 2012-10-17 | — | — | EP | disclosed |
| US-7341716-B2 | Occlusive composition | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2008-03-11 | — | — | US | disclosed |
| EP-1494999-A1 | OCCLUSIVE COMPOSITION COMPRISING A POLY(2-CYANOACRYLATE) MONOMER | Boston Scientific Limited (BB) | 2005-01-12 | — | — | EP | disclosed |
| WO-2003087042-A1 | OCCLUSIVE COMPOSITION COMPRISING A POLY (2-CYANOACRYLATE) MONOMER | BOSTON SCIENTIFIC LIMITED (BB) | 2003-10-23 | — | — | WO | disclosed |
| US-20030194389-A1 | Occlusive composition | STRYKER CORPORATION | 2003-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030194389-A1 | Occlusive composition | C3AR1, F12, FGB | GPR84 495/4885FFAR1 308/4885FFAR4 967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.